Group 1 - The core point of the article is that Brainstorm Cell Therapeutics Inc. (脑动极光-B) has deposited shares worth HKD 396 million into China International Capital Corporation Hong Kong Securities, representing 5.54% of the total [1] - The company announced that it, along with its Hong Kong subsidiary, will subscribe to financial products totaling USD 30 million, with investment scope excluding equity securities, on specific dates in March and April 2025 [1] - As of the announcement date, the financial products subscribed by the company and its Hong Kong subsidiary have been redeemed, and the group has no outstanding principal amount in these financial products [1]

Group 1 - The core point of the article is that Brainstorm Cell Therapeutics Inc. (脑动极光-B) has deposited shares worth HKD 396 million into China International Capital Corporation Hong Kong Securities, representing 5.54% of the total [1] - The company announced that it, along with its Hong Kong subsidiary, will subscribe to financial products totaling USD 30 million, with investment scope excluding equity securities, on specific dates in March and April 2025 [1] - As of the announcement date, the company and its Hong Kong subsidiary have redeemed the subscribed financial products, and the total principal amount of unrecovered financial products for the group is zero [1]

脑动极光-B(06681)发布公告，公司连同香港附属公司分别于2025年3月31日、2025年4月2日及2025年4 月3日认购本金总额为3000万美元的理财产品(其投资范围不包括股本证券)。于本公告日期，公司及香 港附属公司认购的理财产品已赎回，集团尚未赎回的理财产品本金总额为零。 ...

格隆汇12月15日丨脑动极光-B(06681.HK)宣布，公司连同香港附属公司分别于2025年3月31日、2025年4 月2日及2025年4月3日认购本金总额为3000万美元的理财产品(其投资范围不包括股本证券)。于本公告 日期，公司及香港附属公司认购的理财产品已赎回，集团尚未赎回的理财产品本金总额为零。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 上市規則的涵義 由於理財產品於12個月期間內完成向浦銀國際投資管理認購，因此，就根據上 市規則第14.22條計算有關百分比率而言，各認購事項相應本金額已按猶如與浦 銀國際投資管理進行一項交易般予以合計。鑒於在最後認購日期認購事項的最 高適用百分比率超過25%但低於100%，因此，就上市規則而言，認購事項技術 上構成本公司的主要交易而須遵守申報、公告、通函及股東批准規定。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 主要交易 認購及贖回理財產品 董事會宣佈，本公司連同香港附屬公司分別於2025年3月31日、2025年4月2日 及2025年4月3日認購本金總額為30百萬美元的理財產品（其投資範圍不包括股 本證券）。於本公告日期，本公司及香港附屬公司認購的理財產品已贖回，本集 團尚未贖回的理財 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,266,278,000 | | 0 | | 1,266,278,000 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 1,266,278,000 | | 0 | | 1,266,278,000 | 第 2 頁 共 10 頁 v 1.1.1 公司名稱: 腦動極光醫療科技有限公司（於開曼群 ...

Core Viewpoint - The company announced significant changes in its board of directors, including the resignation of Mr. Li Yuezhong and the appointment of new members, which may impact its governance structure and operational leadership [1] Group 1: Board Changes - Mr. Li Yuezhong has resigned as an independent non-executive director and will no longer serve as the chairman of the remuneration committee, a member of the audit committee, and a member of the nomination committee, effective from November 18, 2025 [1] - Mr. Tu Lei has been appointed as an independent non-executive director, chairman of the remuneration committee, and a member of both the audit committee and the nomination committee, effective from November 18, 2025 [1] - Ms. Li Mingqiu and Mr. Lin Xiaobo have been appointed as members of the nomination committee [1] Group 2: Executive Leadership - The company has appointed Mr. Cai Longjun, the current Chief Technology Officer and Chief Operating Officer, as the new Chief Executive Officer, effective immediately [1]

Group 1 - Mr. Li Yuezhong has resigned as an independent non-executive director due to other work commitments and personal time arrangements, effective from November 18, 2025 [1] - Mr. Tu Lei has been appointed as an independent non-executive director, chairman of the remuneration committee, member of the audit committee, and member of the nomination committee, effective from November 18, 2025 [1] - Ms. Li Mingqiu and Mr. Lin Xiaobo have been appointed as members of the nomination committee [1] Group 2 - The company's Chief Technology Officer and Chief Operating Officer, Mr. Cai Longjun, has been appointed as the Chief Executive Officer, effective immediately [1]

腦動極光醫療科技有限公司（「本公司」）根據本公司董事會（「董事會」）於2024年 12月19日通過的一項決議案成立提名委員會（「委員會」）。下文所載為委員會的職 權範圍。職權範圍可供以中英文版本閱覽。職權範圍的中英版本如有任何歧義， 概以英文版本為準。 （股份代號：6681） 提名委員會的職權範圍 （本公司乃根據於2025年11月18日通過的董事會決議案所採納） BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） 2. 釋義 2.1. 就本職權範圍（「職權範圍」）而言： 董事會指本公司的董事會。 首席財務官指董事會不時委任負責管理財務的本公司高級行政人員。 公司秘書指本公司任何公司秘書。 董事指董事會成員。 本集團指於有關期間，本公司及其附屬公司以及聯營公司；或如文義另 有所指，於本公司成為其現時附屬公司及聯營公司的控股公司前期間， 本公司現時附屬公司及聯營公司或其現時附屬公司及聯營公司或其前身 （視乎情況而定）所營運的業務。 1 1. 目的 1.1. 委員會旨在物色、考慮適當候選人擔任本公司董事，並向董事會提出建 議，監察 ...

Core Viewpoint - Brainstorming Aurora-B (06681.HK) announced the resignation of Li Yuezhong as an independent non-executive director effective November 18, 2025, due to other work commitments and personal time arrangements [1] - The company subsequently appointed Tu Lei as an independent non-executive director effective November 18, 2025 [1] Summary by Category - **Director Changes** - Li Yuezhong has resigned from his position as an independent non-executive director effective November 18, 2025 [1] - Tu Lei has been appointed as the new independent non-executive director effective November 18, 2025 [1]